- Home
- PKG vs UTHR Comparison
PKG vs UTHR Comparison
Compare PKG & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PKG
- UTHR
- Stock Information
- Founded
- PKG 1867
- UTHR 1996
- Country
- PKG United States
- UTHR United States
- Employees
- PKG N/A
- UTHR N/A
- Industry
- PKG Containers/Packaging
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- PKG Consumer Discretionary
- UTHR Health Care
- Exchange
- PKG Nasdaq
- UTHR Nasdaq
- Market Cap
- PKG 17.5B
- UTHR 14.4B
- IPO Year
- PKG 2000
- UTHR 1999
- Fundamental
- Price
- PKG $202.35
- UTHR $294.49
- Analyst Decision
- PKG Buy
- UTHR Buy
- Analyst Count
- PKG 6
- UTHR 13
- Target Price
- PKG $218.17
- UTHR $386.15
- AVG Volume (30 Days)
- PKG 734.3K
- UTHR 721.9K
- Earning Date
- PKG 07-23-2025
- UTHR 07-30-2025
- Dividend Yield
- PKG 2.47%
- UTHR N/A
- EPS Growth
- PKG 19.48
- UTHR 18.86
- EPS
- PKG 9.56
- UTHR 25.10
- Revenue
- PKG $8,544,799,999.00
- UTHR $2,994,100,000.00
- Revenue This Year
- PKG $6.62
- UTHR $14.30
- Revenue Next Year
- PKG $3.35
- UTHR $6.32
- P/E Ratio
- PKG $21.16
- UTHR $11.73
- Revenue Growth
- PKG 9.47
- UTHR 19.84
- 52 Week Low
- PKG $172.72
- UTHR $266.98
- 52 Week High
- PKG $250.82
- UTHR $417.82
- Technical
- Relative Strength Index (RSI)
- PKG 66.57
- UTHR 49.14
- Support Level
- PKG $186.28
- UTHR $282.42
- Resistance Level
- PKG $204.18
- UTHR $293.77
- Average True Range (ATR)
- PKG 3.88
- UTHR 7.23
- MACD
- PKG 1.49
- UTHR 0.85
- Stochastic Oscillator
- PKG 90.27
- UTHR 76.67
About PKG Packaging Corporation of America
Packaging Corp. of America is the third-largest containerboard and corrugated packaging manufacturer in the United States. It produces over 5 million tons of containerboard annually. The company's share of the domestic containerboard market is roughly 10%. PCA differentiates itself from larger competitors by focusing on smaller customers and operating with a high degree of flexibility.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.